title: Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib.
abstract: Proteasomal inhibition revolutionized myeloma therapies in this decade of novel agents. The only US Food and Drug Administration approved proteasome inhibitor so far, bortezomib effectively targets the constitutive proteasome subunit β5 of the 26S proteasome. Bortezomib induces high and quality response rates that are durable. However, myeloma cells acquire resistance to bortezomib through various mechanisms. Further, grade 3/4 peripheral neuropathy is seen in up to a quarter of patients treated with bortezomib. While the recent change in the mode of administration via the subcutaneous route is associated with a lower incidence of grade 3/4 peripheral neuropathy, it remains a major concern. The second generation proteasome inhibitors are promising, with increased preclinical efficacy and a better administration schedule. The current review spotlights the second generation proteasome inhibitors with special focus on the safety and efficacy of carfilzomib, an epoxyketone with lesser peripheral neuropathy, which exhibits irreversible proteasome inhibition. In this article, we review the pharmacology and preclinical and clinical efficacy and safety of carfilzomib alone and in combination with other chemotherapeutic agents in the various lymphoid neoplasms and multiple myeloma as well as ongoing clinical trials.
authors: Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta GA, USA.
authors: Ajay
authors: A
authors: Nooka
authors: Charise
authors: C
authors: Gleason
authors: Daniela
authors: D
authors: Casbourne
authors: Sagar
authors: S
authors: Lonial
keywords: carfilzomib; epoxyketone; myeloma; proteasome inhibitor; second generation
references: J Peripher Nerv Syst. 2008 Mar;13(1):27-46
references: 18346229
references: J Med Chem. 2009 May 14;52(9):3028-38
references: 19348473
references: Cancer Cell. 2005 Nov;8(5):407-19
references: 16286248
references: Blood. 2010 Aug 5;116(5):679-86
references: 20385792
references: Blood. 2010 Jan 28;115(4):834-45
references: 19965674
references: Lancet Oncol. 2011 May;12(5):431-40
references: 21507715
references: Blood. 2008 Sep 1;112(5):1593-9
references: 18574024
references: Br J Cancer. 2006 Oct 23;95(8):961-5
references: 17047643
references: Proc Natl Acad Sci U S A. 2004 Jan 13;101(2):540-5
references: 14695887
references: Leukemia. 2006 Sep;20(9):1467-73
references: 16855634
references: Blood. 2007 Nov 1;110(9):3281-90
references: 17591945
references: Drug Metab Dispos. 2011 Oct;39(10):1873-82
references: 21752943
references: J Med Chem. 2008 Feb 28;51(4):1068-72
references: 18247547
references: Br J Haematol. 2007 Mar;136(6):814-28
references: 17341267
references: Mol Aspects Med. 2009 Aug;30(4):191-296
references: 19371762
references: Blood. 2008 Sep 15;112(6):2177-8
references: 18779399
references: Blood. 2010 Dec 2;116(23):4745-53
references: 20807892
references: Nat Rev Drug Discov. 2006 Sep;5(9):769-84
references: 16955068
references: Blood. 2009 Oct 15;114(16):3439-47
references: 19671918
references: Cancer Res. 2007 Jul 1;67(13):6383-91
references: 17616698
references: J Biol Chem. 2006 Mar 31;281(13):8582-90
references: 16455650
references: Drug Discov Today. 2010 Mar;15(5-6):243-9
references: 20116451
references: Leukemia. 2009 Aug;23(8):1507-14
references: 19282831
references: Clin Cancer Res. 2009 Aug 15;15(16):5250-7
references: 19671864
references: Lancet. 2010 Dec 18;376(9758):2075-85
references: 21146205
references: Clin Cancer Res. 2011 Apr 1;17(7):1753-64
references: 21355079
references: Clin Cancer Res. 2011 May 1;17(9):2734-43
references: 21364033
references: Nat Cell Biol. 1999 Aug;1(4):221-6
references: 10559920
references: Clin Cancer Res. 2006 May 15;12(10):2955-60
references: 16707588
references: J Clin Oncol. 2002 Nov 15;20(22):4420-7
references: 12431963
references: Blood. 2008 Mar 1;111(5):2765-75
references: 18057228
references: Blood. 2010 Jun 3;115(22):4478-87
references: 20233973
references: Mol Cancer Ther. 2011 Sep;10(9):1686-97
references: 21750224
references: Mol Cell. 2006 Oct 6;24(1):39-50
references: 17018291
references: Semin Cell Dev Biol. 2000 Jun;11(3):141-8
references: 10906270
references: Nat Methods. 2005 May;2(5):357-62
references: 15846363
references: Chem Biol. 1999 Nov;6(11):811-22
references: 10574782
references: Blood. 2010 Dec 2;116(23):4906-15
references: 20805366
references: Cancer Res. 2010 Mar 1;70(5):1970-80
references: 20160034
references: Mol Cancer Ther. 2011 Nov;10(11):2034-42
references: 22072815
references: Mol Cell. 2008 May 9;30(3):360-8
references: 18471981
references: Cardiovasc Hematol Disord Drug Targets. 2009 Mar;9(1):62-77
references: 19275578
references: Blood. 2005 Dec 1;106(12):3777-84
references: 16099887
references: J Exp Med. 1998 Jan 5;187(1):97-104
references: 9419215
references: Blood. 2008 Sep 15;112(6):2489-99
references: 18565852
references: Clin Cancer Res. 2009 Nov 15;15(22):7085-91
references: 19903785
references: Arch Biochem Biophys. 2000 Nov 1;383(1):1-16
references: 11097171
references: Eur J Cancer. 2006 Dec;42(18):3095-102
references: 17084074